Sign In
Buy NDAQ
$81.61
-0.88 (-1.07%)
At Close: Jun 24, 2026
Nasdaq Jumps Over 1% Despite China's Trade Concerns As Palantir, Spotify Surge: Greed Index Remains In 'Fear' Zone
02:41am, Wednesday, 05'th Feb 2025
The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the “Fear” zone on Tuesday.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Tuesday, 04'th Feb 2025
BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for
Veea to Ring the Nasdaq Opening Bell on February 5, 2025
04:55pm, Tuesday, 04'th Feb 2025
NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veea, Inc. (NASDAQ: VEEA), a pioneering technology company specializing in edge computing and AI with smart connectivity solutions, today announced that it
ReTo Announces Receipt of Nasdaq Delisting Determination and Plan to Appeal
04:30pm, Tuesday, 04'th Feb 2025
BEIJING , Feb. 4, 2025 /PRNewswire/ -- ReTo Eco-Solutions, Inc. (Nasdaq: RETO) ("ReTo" or the "Company"), a manufacturer of equipment for production of eco-friendly materials in China, today announced
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 04'th Feb 2025
SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, d
Nasdaq Index: Alphabet's Earnings Shock—Stock Drops 6% After Hours on Revenue Miss
04:21pm, Tuesday, 04'th Feb 2025
Alphabet stock drops 6% after a Q4 revenue miss despite an EPS beat. Traders react to weak cloud growth—what's next for Nasdaq and tech stocks?
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:10pm, Tuesday, 04'th Feb 2025
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options
Nasdaq CEO Adena Friedman to Present at the 2025 UBS Financial Services Conference
04:05pm, Tuesday, 04'th Feb 2025
NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) will be presenting at the following conference, with a webcast available at Nasdaq's Investor Relations website: ir.nasdaq.com/events.
Nasdaq Reports January 2025 Volumes
04:05pm, Tuesday, 04'th Feb 2025
NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today reported monthly volumes for January 2025 on its Investor Relations website. A data sheet showing this information can be found
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 04'th Feb 2025
CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 04'th Feb 2025
WALTHAM, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the company approved the grant of equity awards to three new employees with a grant
Carbon Revolution Announces Receipt of Extension from Nasdaq Stock Market
04:05pm, Tuesday, 04'th Feb 2025
GEELONG, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Carbon Revolution plc (Nasdaq: CREV) (the “Company”), a Tier 1 OEM supplier and the leading global manufacturer of lightweight advanced techno
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 04'th Feb 2025
CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 04'th Feb 2025
SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s
Nasdaq Surges Over 1%; Pfizer Earnings Top Estimates
12:21pm, Tuesday, 04'th Feb 2025
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Tuesday.
